Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael Itzykson

Showing results (1-10 of 97) with videos related to

Pageof 10
Sort By:
Best Practice & Research. Clinical Haematology|May 29, 2020
Contemporary treatment approaches to CMML - Is allogeneic HCT the only cure?Marie Robin, Raphael Itzykson
Bulletin Du Cancer|August 9, 2011
[Hypomethylating agents for the treatment of myelodysplastic syndromes]Raphael Itzykson, Pierre Fenaux
Current Opinion in Hematology|May 27, 2009
Optimal sequencing of treatments for patients with myelodysplastic syndromesRaphael Itzykson, Pierre Fenaux
International Journal of Hematology|April 26, 2019
Clinical update on hypomethylating agentsMatthieu Duchmann, Raphael Itzykson
Blood|June 3, 2017
How I treat chronic myelomonocytic leukemiaEric Solary, Raphael Itzykson
Hematology. American Society of Hematology. Education Program|December 10, 2017
How and when to decide between epigenetic therapy and chemotherapy in patients with AMLHervé Dombret, Raphael Itzykson
Current Oncology Reports|February 5, 2019
New Treatment Options for Acute Myeloid Leukemia in 2019Marco Cerrano, Raphael Itzykson
Current Opinion in Hematology|January 18, 2012
Optimizing hypomethylating agents in myelodysplastic syndromesRaphael Itzykson, Pierre Fenaux
Leukemia & Lymphoma|November 4, 2024
Single-cell sequencing applications in acute myeloid leukemiaNicolas Lecornec, Matthieu Duchmann, Raphael Itzykson
Lancet (London, England)|March 25, 2014
Myelodysplastic syndromesLionel Adès, Raphael Itzykson, Pierre Fenaux
Pageof 10

Showing results (1-10 of 97) with videos related to

Sort By:
Pageof 10
Best Practice & Research. Clinical Haematology|May 29, 2020
Contemporary treatment approaches to CMML - Is allogeneic HCT the only cure?Marie Robin, Raphael Itzykson
Bulletin Du Cancer|August 9, 2011
[Hypomethylating agents for the treatment of myelodysplastic syndromes]Raphael Itzykson, Pierre Fenaux
Current Opinion in Hematology|May 27, 2009
Optimal sequencing of treatments for patients with myelodysplastic syndromesRaphael Itzykson, Pierre Fenaux
International Journal of Hematology|April 26, 2019
Clinical update on hypomethylating agentsMatthieu Duchmann, Raphael Itzykson
Blood|June 3, 2017
How I treat chronic myelomonocytic leukemiaEric Solary, Raphael Itzykson
Hematology. American Society of Hematology. Education Program|December 10, 2017
How and when to decide between epigenetic therapy and chemotherapy in patients with AMLHervé Dombret, Raphael Itzykson
Current Oncology Reports|February 5, 2019
New Treatment Options for Acute Myeloid Leukemia in 2019Marco Cerrano, Raphael Itzykson
Current Opinion in Hematology|January 18, 2012
Optimizing hypomethylating agents in myelodysplastic syndromesRaphael Itzykson, Pierre Fenaux
Leukemia & Lymphoma|November 4, 2024
Single-cell sequencing applications in acute myeloid leukemiaNicolas Lecornec, Matthieu Duchmann, Raphael Itzykson
Lancet (London, England)|March 25, 2014
Myelodysplastic syndromesLionel Adès, Raphael Itzykson, Pierre Fenaux
Pageof 10